Myelodysplastic Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region & Competition, 2021-2031F

Description

The Global Myelodysplastic Syndrome (MDS) Treatment Market is projected to expand from USD 3.04 Billion in 2025 to USD 4.33 Billion by 2031, reflecting a compound annual growth rate of 6.07%. Treatments for MDS, which range from hypomethylating agents and immunomodulators to hematopoietic stem cell transplantation, aim to reinstate normal bone marrow activity and halt the progression to acute myeloid leukemia. A key factor driving this growth is the aging global population, as these bone marrow failure disorders are frequently associated with advancing age, while improved diagnostic techniques are uncovering previously undetected cases, ensuring a steady demand for medical interventions.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 3.04 Billion
Market Size 2031	USD 4.33 Billion
CAGR 2026-2031	6.07%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Despite these favorable conditions, the market confronts substantial hurdles due to the clinical heterogeneity of the disease, which makes accurate diagnosis and targeted therapy selection difficult. This complexity often results in poor treatment adherence and significant management challenges for patients. For example, the MDS Alliance reported in 2024 that 45% of patients were unaware of their specific MDS subtype, a lack of diagnostic clarity that limits the effective use of advanced therapies and restricts the potential growth of the specialized treatment sector.

Market Driver

A strong pipeline of innovative therapeutic agents is fundamentally transforming the Global MDS Treatment Market, moving the standard of care from merely supportive measures to disease-modifying interventions. Developers are prioritizing telomerase inhibitors and other new mechanisms to overcome the shortcomings of traditional erythropoiesis-stimulating agents, especially for patients dependent on transfusions. This innovation is vital given the disease's poor prognosis; the American Society of Clinical Oncology noted in March 2024 that the 5-year relative survival rate is around 37%. Regulatory successes underscore this progress, such as Geron Corporation's June 2024 announcement regarding the FDA approval of Rytelo, where the IMerge Phase 3 trial showed a 39.8% red blood cell transfusion independence rate for at least eight weeks with imetelstat.

In parallel, the rise of targeted and immunomodulatory therapies is fueling market growth by allowing for more precise treatment of specific disease subtypes, particularly in first-line settings. These therapies, which address specific biological pathways and maturation defects, are seeing increased adoption and generating significant commercial value over older, non-specific treatments. This shift is reflected in the financial results of major players; Bristol Myers Squibb reported in October 2024 that worldwide revenues for Reblozyl jumped 80% to $447 million, driven by robust demand in first-line MDS treatment, indicating a market consolidation around high-value pharmacotherapies that deliver better outcomes than traditional care.

Market Challenge

The clinical heterogeneity inherent in Myelodysplastic Syndromes poses a major constraint on the growth of the global treatment market. Since the disease manifests with diverse biological features and progression speeds, physicians often struggle to pinpoint accurate diagnoses and determine the best therapeutic courses. This variability frequently results in delayed treatment or the choice of suboptimal management plans, thereby dampening the utilization of targeted pharmacotherapies and creating barriers for manufacturers attempting to widely distribute drugs tailored to specific biological subtypes.

Such diagnostic complexity fragments the patient base and curbs the revenue potential for advanced treatments. Without precise classification, patients are frequently assigned to general supportive care rather than receiving high-value active therapies. Although the American Cancer Society estimates that 13,000 new MDS cases will be diagnosed in the United States in 2025, the absence of a standardized disease presentation prevents the market from fully addressing this demand, as diagnostic uncertainty limits the consistent prescription of premium medical interventions.

Market Trends

The shift toward Oral Hypomethylating Agents is significantly reshaping the treatment landscape by moving care from intravenous infusions to home-based regimens. This trend mitigates the logistical challenges of chronic parenteral therapies, providing a more convenient option that aids adherence and decreases the frequency of clinic visits. Real-world data supports the safety of this transition; an abstract from the American Society of Hematology in November 2025 revealed that patients on oral decitabine-cedazuridine had a notably lower incidence of febrile neutropenia during the first two cycles-17% compared to 55% for those on parenteral agents-highlighting the potential for fewer hospitalizations.

At the same time, the market is characterized by a surge in Combination Therapy Clinical Trials, where pharmaceutical companies are testing hypomethylating agents paired with novel mechanisms like BCL-2 inhibition to surpass the efficacy limits of monotherapy. While this research aims to enhance survival in higher-risk groups through synergistic pathways, achieving statistically significant clinical results remains difficult. For instance, AbbVie announced in June 2025 that the pivotal Phase 3 VERONA trial, testing venetoclax combined with azacitidine in newly diagnosed higher-risk patients, failed to meet its primary overall survival endpoint, showing a hazard ratio of 0.908.

Key Market Players

AbbVie Inc.
Accord Healthcare Limited
Bristol-Myers Squibb Company
Jazz Pharmaceuticals Inc.
Novartis AG
Lupin Limited
Otsuka America Pharmaceutical Inc.
Takeda Pharmaceutical Company Limited
Astex Therapeutics Limited
Pfizer Inc.

Report Scope

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type

Stem Cell Transplant
Immune Treatments
Chemotherapy
Immunomodulatory Drugs
Anti-anemics
Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User

Hospitals & Clinics
Ambulatory Care Centers
Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Global Myelodysplastic Syndrome (MDS) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
- 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment Type
    - 6.3.3.2.2. By End User

7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment Type
    - 7.3.1.2.2. By End User
- 7.3.2. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment Type
    - 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment Type
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment Type
    - 7.3.5.2.2. By End User

8. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment Type
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment Type
    - 8.3.1.2.2. By End User
- 8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment Type
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment Type
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment Type
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment Type
    - 8.3.5.2.2. By End User

9. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment Type
    - 9.3.1.2.2. By End User
- 9.3.2. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment Type
    - 9.3.2.2.2. By End User
- 9.3.3. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment Type
    - 9.3.3.2.2. By End User

10. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment Type
    - 10.3.1.2.2. By End User
- 10.3.2. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment Type
    - 10.3.2.2.2. By End User
- 10.3.3. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Myelodysplastic Syndrome (MDS) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AbbVie Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Accord Healthcare Limited
15.3. Bristol-Myers Squibb Company
15.4. Jazz Pharmaceuticals Inc.
15.5. Novartis AG
15.6. Lupin Limited
15.7. Otsuka America Pharmaceutical Inc.
15.8. Takeda Pharmaceutical Company Limited
15.9. Astex Therapeutics Limited
15.10. Pfizer Inc.